EUCTR2007-004406-26-BE进行中（未招募）不适用
Comparison of M-Vax plus Low Dose Interleukin-2 versus Placebo Vaccine plus Low Dose Interleukin-2 in patients with Stage IV Melanoma - BB-IND #10658
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 387
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Stage IV metastatic melanoma of cutaneous or mucosal origin or without known primary site
- •- At least one metastatic mass that is surgically resectable, excluding metastases in brain, bowel, or bone
- •- Successful preparation of a vaccine that meets quality control release criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Failure to prepare a vaccine that meets all quality control release criteria
- •- Uveal melanoma
- •- Brain metastases, current or past (unless successfully treated at least one year prior to enrolment)
- •- Known gentamicin allergy
研究者
相似试验
进行中（未招募）
1 期
Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID)Mucous Membrane Pemphigoid, Primary Sclerosing Cholangitis (PSC), Pemphigus vulgaris / foliaceus, Polymyositis/ DermatomyositisMedDRA version: 20.0Level: LLTClassification code: 10057069Term: Pemphigus foliaceus Class: 10040785MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805MedDRA version: 20.0Level: LLTClassification code: 10052802Term: Pemphigus vulgaris Class: 10040785MedDRA version: 20.0Level: PTClassification code: 10012503Term: Dermatomyositis Class: 100000004858MedDRA version: 20.0Level: PTClassification code: 10036102Term: Polymyositis Class: 100000004859MedDRA version: 25.0Level: PTClassification code: 10087064Term: Mucous membrane pemphigoid Class: 100000004858CTIS2023-510297-14-00niversitaetsklinikum Schleswig-Holstein AöR112
尚未招募
不适用
Immunogenicity of oral polio vaccine in different doses in MozambiquepoliomyelitisInfection - Other infectious diseasesACTRN12619000184178WHO360
进行中（未招募）
1 期
Efficacy and safety of low-dose IL-2 (ld-IL-2) as a Treg enhancer for controlling neuro-inflammation in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patientsEUCTR2015-005347-14-GBCHU DE NIMES216
尚未招募
不适用
Comparing the Combination of Dexmedetomidine and Lidocaine Infusion With Intravenous Lidocaine Infusion in Attenuating heart rate and blood pressure response to Laryngoscopy and Endotracheal Intubation in patients undergoing general anaesthesia.CTRI/2022/11/047632Department of Anaesthesia
尚未招募
4 期
Comparison Between Intralesional MMR vaccine and Intralesional Vit D in treatment of Plane WartsCTRI/2023/08/055966MAMC